NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer with Exploratory Biomarker CorrelativesRobert L. Ferris, Julie E. Bauman, Jie Chen et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 0
Cellular Immune and Genomic Biomarkers in NRG-HN003, a Phase I Study Adding Pembrolizumab to Adjuvant Cisplatin and Radiation Therapy (CRT) in Pathologically High-Risk Head and Neck Cancer (HNSCC)Julie E. Bauman, Robert L. Ferris, J. Harris et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 0